Drug major Dr Reddy's Laboratories has entered into a licencing agreement with US-based biopharma company XenoPort for the development and commercialisation of a latter's oral-based drug. Under the deal, Dr Reddy's will pay an upfront fee of $50 million and up to $440 million later. The company plans to develop the drug as a potential treatment for chronic plaque psoriasis. 